Amino WireFDA, DOJ and court actions on peptides, lab-testing explainers (HPLC, mass spec, COAs, endotoxin) and sourced, dated vendor status logs. No rankings.https://aminowire.news/enNew South Wales counts 1,180 emergency visits tied to unapproved peptides, most of them naming retatrutidehttps://aminowire.news/news/2026/10/nsw-peptide-emergency-visits-retatrutide/https://aminowire.news/news/2026/10/nsw-peptide-emergency-visits-retatrutide/NSW Health data: 1,180 emergency department visits linked to unapproved peptides from July 2025 to September 2026. What the count shows, and what it cannot.Mon, 19 Oct 2026 19:11:46 GMTmarketretatrutideNSW HealthAustraliaTGAblack marketBPC-157adverse eventsEli Lilly dismisses its retatrutide lawsuits against Texas Peptides and Lone Star Peptide, with prejudicehttps://aminowire.news/news/2026/10/lilly-drops-retatrutide-suits-texas-peptides-lone-star/https://aminowire.news/news/2026/10/lilly-drops-retatrutide-suits-texas-peptides-lone-star/Court filings show Lilly voluntarily dismissed two August retatrutide suits on Oct 15 and 16, 2026, with prejudice. No reason given. Where all 11 cases stand.Mon, 19 Oct 2026 19:11:46 GMTcourtsEli Lillyretatrutidelawsuitsresearch use onlyTexasCourtListenerConsumer group asks FDA to reject advisory votes for BPC-157 and five other peptides, citing conflictshttps://aminowire.news/news/2026/10/cspi-urges-fda-reject-pcac-peptide-votes/https://aminowire.news/news/2026/10/cspi-urges-fda-reject-pcac-peptide-votes/On Oct 14, 2026 CSPI asked Acting FDA Commissioner Kyle Diamantas to reject the July PCAC votes on six peptides. What the letter argues and what it asks.Mon, 19 Oct 2026 00:00:00 GMTregulationCSPIPCAC503A bulks listBPC-157conflict of interestFDAFDA’s ‘Interim Access Policy’ for compounded peptides lands at OMB for reviewhttps://aminowire.news/news/2026/10/peptide-interim-access-policy-omb-review/https://aminowire.news/news/2026/10/peptide-interim-access-policy-omb-review/FDA's Interim Access Policy for Compounding Using Certain Peptides (RIN 0910-ZD94) reached OMB review on Oct 14, 2026. What is known, and what is not final.Mon, 19 Oct 2026 00:00:00 GMTregulationFDAOMB503ABPC-157enforcement discretionFederal jury convicts Texas man who ran Pinned Aminos websites selling drugs labeled 'research compounds'https://aminowire.news/news/2026/09/pinned-aminos-seller-convicted/https://aminowire.news/news/2026/09/pinned-aminos-seller-convicted/A New Haven jury convicted Ryan Fields on Sept 18, 2026 over pinnedaminos.com and projectaminos.com. Charges, evidence cited and the co-defendant's sentence.Mon, 19 Oct 2026 00:00:00 GMTcourtsDOJresearch use onlyjury verdictPinned AminosConnecticutFDA warns five online peptide sellers over semaglutide, retatrutide, SS-31, PT-141, tesamorelin and morehttps://aminowire.news/news/2026/08/fda-warning-letters-five-peptide-sellers/https://aminowire.news/news/2026/08/fda-warning-letters-five-peptide-sellers/FDA warning letters dated Aug 24, 2026 went to Royal Peptides, Tex Peptides, NuScience, Peak Performance and Peptide Partners. What each letter says.Mon, 19 Oct 2026 00:00:00 GMTenforcementFDA warning lettersresearch use onlyretatrutideBAC waterParadigm Peptides owner sentenced to nearly six years for selling unapproved drugs labeled ‘research use only’https://aminowire.news/news/2026/07/paradigm-peptides-owner-sentenced/https://aminowire.news/news/2026/07/paradigm-peptides-owner-sentenced/Matthew Kawa, owner of Paradigm Peptides, was sentenced on July 30, 2026 in federal court in Indiana. Court record, plea facts and what prosecutors said.Mon, 19 Oct 2026 00:00:00 GMTcourtsDOJParadigm Peptidesresearch use onlyCOA fraudsentencingFDA advisers back BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon for the 503A bulks listhttps://aminowire.news/news/2026/07/pcac-votes-six-peptides/https://aminowire.news/news/2026/07/pcac-votes-six-peptides/At its July 23-24, 2026 meeting the Pharmacy Compounding Advisory Committee backed six of seven peptides against FDA staff advice. Votes, caveats, next steps.Mon, 19 Oct 2026 00:00:00 GMTregulationPCAC503A bulks listBPC-157TB-500KPVMOTS-cSemaxEpitalonDSIPMichigan man gets 21 months for selling China-sourced GLP-1s labeled 'for research purposes only'https://aminowire.news/news/2026/07/michigan-research-glp-1-seller-sentenced/https://aminowire.news/news/2026/07/michigan-research-glp-1-seller-sentenced/Brandon Piper of Gobles, Mich. was sentenced on July 23, 2026 for a misbranded-drug conspiracy run through MilestonePurity.com. What DOJ said.Mon, 19 Oct 2026 00:00:00 GMTcourtsDOJsemaglutidetirzepatideresearch use onlysentencingMichiganLouisiana Act 374 bars licensing boards from blocking compliant compounded peptideshttps://aminowire.news/news/2026/05/louisiana-act-374-peptides/https://aminowire.news/news/2026/05/louisiana-act-374-peptides/Louisiana's SB 253, signed May 22, 2026 as Act 374, limits how state boards can regulate compounded peptides. Text, votes, effective date and limits.Mon, 19 Oct 2026 00:00:00 GMTregulationstate lawLouisianacompounding503A503Bpharmacy boardFDA to put LL-37, GHK-Cu, dihexa, Melanotan II and PEG-MGF before its advisers by February 2027https://aminowire.news/news/2026/04/fda-plans-pcac-ll-37-ghk-cu-melanotan-ii/https://aminowire.news/news/2026/04/fda-plans-pcac-ll-37-ghk-cu-melanotan-ii/FDA posted an early notice on April 15, 2026 for a PCAC meeting on five more peptides, to be held before the end of February 2027. What is and isn't set.Mon, 19 Oct 2026 00:00:00 GMTregulationPCAC503A bulks listLL-37GHK-CuMelanotan IIdihexaPEG-MGFFDA moves 12 peptides out of compounding Category 2 after nominations withdrawn, schedules advisory reviewhttps://aminowire.news/news/2026/04/fda-removes-peptides-from-category-2/https://aminowire.news/news/2026/04/fda-removes-peptides-from-category-2/On April 15, 2026 FDA said BPC-157, TB-500 and 10 other peptides would leave 503A Category 2. Why that is not permission to compound, and what followed.Mon, 19 Oct 2026 00:00:00 GMTregulationCategory 2503ABPC-157TB-500KennedyGrand jury indicts Utah osteopathic physician on misbranded-drug charges over peptides sold to patientshttps://aminowire.news/news/2026/04/utah-physician-indicted-peptides/https://aminowire.news/news/2026/04/utah-physician-indicted-peptides/DOJ says a Utah physician obtained unapproved peptides from China, relabeled them and sold them to 200+ patients. What the April 1, 2026 indictment alleges.Mon, 19 Oct 2026 00:00:00 GMTcourtsDOJFDA-OCImisbrandingindictmentFDA warning letters to Gram Peptides and Prime Sciences cite retatrutide, tirzepatide and bacteriostatic waterhttps://aminowire.news/news/2026/03/fda-warning-letters-retatrutide-sellers/https://aminowire.news/news/2026/03/fda-warning-letters-retatrutide-sellers/FDA letters dated March 31, 2026 to Gram Peptides and Prime Sciences call their GLP-1-class products and BAC water unapproved new drugs despite RUO labels.Mon, 19 Oct 2026 00:00:00 GMTenforcementFDA warning lettersretatrutideBAC waterresearch use onlyPeptide Sciences announces voluntary shutdown, replacing storefront with a three-sentence noticehttps://aminowire.news/news/2026/03/peptide-sciences-shutdown/https://aminowire.news/news/2026/03/peptide-sciences-shutdown/Peptide Sciences closed on March 6, 2026, calling it voluntary. What the notice said, how it changed, and what is still unknown about why it closed.Mon, 19 Oct 2026 00:00:00 GMTmarketPeptide Sciencesvendor shutdownmarketHHS Secretary Kennedy tells Joe Rogan he is ‘a big fan of peptides’ and expects FDA action on about 14https://aminowire.news/news/2026/02/kennedy-rogan-peptides/https://aminowire.news/news/2026/02/kennedy-rogan-peptides/On the Feb 27, 2026 Joe Rogan Experience, HHS Secretary Robert F. Kennedy Jr. said he hoped peptides would be available from 'ethical suppliers'. What followed.Mon, 19 Oct 2026 00:00:00 GMTregulationKennedyHHSCategory 2policyFDA says it will restrict GLP-1 ingredients for mass-marketed compounded drugs and names Hims & Hershttps://aminowire.news/news/2026/02/fda-moves-against-mass-marketed-compounded-glp-1s/https://aminowire.news/news/2026/02/fda-moves-against-mass-marketed-compounded-glp-1s/In a Feb 6, 2026 statement, FDA Commissioner Makary said FDA would restrict GLP-1 APIs used in mass-marketed compounded drugs. What he said, quoted.Mon, 19 Oct 2026 00:00:00 GMTregulationFDAGLP-1compoundingsemaglutidetirzepatideHims & HersadvertisingScience.bio posts ‘Permanently Closed’ notice and stops selling research productshttps://aminowire.news/news/2026/01/science-bio-closes/https://aminowire.news/news/2026/01/science-bio-closes/Science.bio closed in late January 2026. What its public notice says, what a customer email reportedly cited, and what is not on the record.Mon, 19 Oct 2026 00:00:00 GMTmarketScience.biovendor shutdownnootropicsresearch chemicalsWADA's 2026 Prohibited List keeps BPC-157 banned and adds peptide-hormone exampleshttps://aminowire.news/news/2025/09/wada-2026-prohibited-list-peptides/https://aminowire.news/news/2025/09/wada-2026-prohibited-list-peptides/WADA published its 2026 Prohibited List on Sept 24, 2025, in force Jan 1, 2026. Where BPC-157, TB-500, MOTS-c, CJC-1295 and ipamorelin sit.Mon, 19 Oct 2026 00:00:00 GMTregulationWADAanti-dopingBPC-157TB-500MOTS-csportFDA letters call online sellers' retatrutide an unapproved drug and their GLP-1 claims misleadinghttps://aminowire.news/news/2025/09/fda-warning-letters-glp1-retatrutide-sept-2025/https://aminowire.news/news/2025/09/fda-warning-letters-glp1-retatrutide-sept-2025/FDA's Sept 9, 2025 warning letters to GLP-1 Solution, GenLabMeds, SimpleRx and Slendid. What each letter cited, from retatrutide to 'same as' claims.Mon, 19 Oct 2026 00:00:00 GMTenforcementFDA warning letterretatrutidesemaglutidetirzepatidecompoundingGLP-1Kentucky physician pleads guilty to giving patients unapproved semaglutide labeled for lab researchhttps://aminowire.news/news/2025/04/ashland-doctor-pleads-guilty-research-semaglutide/https://aminowire.news/news/2025/04/ashland-doctor-pleads-guilty-research-semaglutide/Ashland, Ky. physician Matthew Lewis pleaded guilty in April 2025 to receiving misbranded semaglutide. What DOJ said, and the sentence later reported.Mon, 19 Oct 2026 00:00:00 GMTcourtsDOJsemaglutideresearch use onlyphysicianKentuckyFDA warning letter to USApeptide.com says 'research use only' labels did not change what the products were forhttps://aminowire.news/news/2025/02/usapeptide-warning-letter-semaglutide/https://aminowire.news/news/2025/02/usapeptide-warning-letter-semaglutide/FDA's Feb 26, 2025 warning letter to USApeptide.com, listed in Germany, cited semaglutide and tirzepatide sold to US buyers despite 'research use only' labels.Mon, 19 Oct 2026 00:00:00 GMTenforcementFDA warning letterresearch use onlysemaglutidetirzepatideUSApeptideFDA declares semaglutide shortage resolved, giving compounders until April and May 2025 to stop copieshttps://aminowire.news/news/2025/02/fda-ends-semaglutide-shortage-compounding/https://aminowire.news/news/2025/02/fda-ends-semaglutide-shortage-compounding/On Feb 21, 2025 FDA said the semaglutide injection shortage was over, two months after tirzepatide. The wind-down dates for 503A and 503B compounders.Mon, 19 Oct 2026 00:00:00 GMTregulationsemaglutidetirzepatidedrug shortage503A503BGLP-1FDA reissues its finding that the Mounjaro and Zepbound shortage is over after a court remandhttps://aminowire.news/news/2024/12/fda-tirzepatide-shortage-resolved/https://aminowire.news/news/2024/12/fda-tirzepatide-shortage-resolved/On Dec 19, 2024 FDA issued a declaratory order that the tirzepatide injection shortage was resolved, replacing its Oct 2 decision. What the order says.Mon, 19 Oct 2026 00:00:00 GMTregulationtirzepatidedrug shortagecompoundingMounjaroZepboundGLP-1FDA letters to Swisschems and Summit Research Peptides: ‘research use only’ labels don’t change drug statushttps://aminowire.news/news/2024/12/fda-warning-letters-research-use-only-labels/https://aminowire.news/news/2024/12/fda-warning-letters-research-use-only-labels/FDA letters dated Dec 10, 2024 to sellers of semaglutide and retatrutide set out why RUO labels did not protect them. The legal test FDA applied.Mon, 19 Oct 2026 00:00:00 GMTenforcementFDA warning lettersresearch use onlysemaglutideretatrutideintended useFDA compounding advisers vote against CJC-1295, AOD-9604 and thymosin alpha-1 for the 503A bulks listhttps://aminowire.news/news/2024/12/pcac-rejects-cjc-1295-aod-9604-thymosin/https://aminowire.news/news/2024/12/pcac-rejects-cjc-1295-aod-9604-thymosin/At its Dec 4, 2024 meeting, FDA's compounding advisory committee voted against CJC-1295, AOD-9604 and thymosin alpha-1. Vote counts from the final minutes.Mon, 19 Oct 2026 00:00:00 GMTregulationPCAC503A bulks listCJC-1295AOD-9604thymosin alpha-1FDAFDA advisers vote against ipamorelin, kisspeptin-10, ibutamoren and L-theanine for the 503A listhttps://aminowire.news/news/2024/10/pcac-rejects-ipamorelin-kisspeptin-ibutamoren/https://aminowire.news/news/2024/10/pcac-rejects-ipamorelin-kisspeptin-ibutamoren/At its Oct 29, 2024 meeting, FDA's Pharmacy Compounding Advisory Committee voted against four nominated substances. The vote counts from the final minutes.Mon, 19 Oct 2026 00:00:00 GMTregulationPCAC503A bulks listipamorelinkisspeptin-10ibutamorenFDA